Payment overview · 2025
General Payments
$1,002.97
46 reported records · 14 companies
Healthcare provider profile · identity verified
Randall Johnson, PA-C
Physician Assistants & Advanced Practice Nursing Providers|Physician Assistant · KALAMAZOO, MI · NPI 1407338627
Verified facts
What the public records show
CMS Open Payments records show Randall Johnson, PA-C received $1,002.97 in general payments during 2025 across 46 reported records.
ABBVIE INC. accounted for 32.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 17 associated products.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABILIFY MAINTENA as an associated drug or biological on 2902 records involving 986 distinct recipient NPIs. Public Medicare Part D data also shows 57 claims for Abilify Maintena by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Rexulti by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $323.51 | 32.3% | 17 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $91.25 | 9.1% | 4 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $81.30 | 8.1% | 3 | 2025 |
| TG Therapeutics, Inc. | Unresolved — no canonical attribution shown | $79.45 | 7.9% | 3 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $75.01 | 7.5% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $66.20 | 6.6% | 4 | 2025 |
| SK Life Science, Inc. |
SK Life Science, Inc. exact · evidence 2025-04-03 |
$53.41 | 5.3% | 2 | 2025 |
| Genentech USA, Inc. | Unresolved — no canonical attribution shown | $52.74 | 5.3% | 2 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $48.47 | 4.8% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $38.39 | 3.8% | 2 | 2025 |
| Aucta Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $26.77 | 2.7% | 1 | 2025 |
| Dynasplint Systems Inc. | Unresolved — no canonical attribution shown | $25.33 | 2.5% | 1 | 2025 |
| ACADIA Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $21.79 | 2.2% | 1 | 2025 |
| Neurelis, Inc. |
Neurelis, Inc. exact · evidence 2025-02-20 |
$19.35 | 1.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,002.97 | 46 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $279.10 | 15 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $279.10 | 15 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $91.25 | 4 | 2025 |
Source payment records
|
|||||
| Nayzilam Normalized: nayzilam |
Drug | UCB, Inc. | $81.30 | 3 | 2025 |
Source payment records
|
|||||
| BRIUMVI Normalized: briumvi |
Drug | TG Therapeutics, Inc. | $79.45 | 3 | 2025 |
Source payment records
|
|||||
| KESIMPTA Normalized: kesimpta |
Drug | Novartis Pharmaceuticals Corporation | $75.01 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $66.20 | 4 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $66.20 | 4 | 2025 |
Source payment records
|
|||||
| Ocrevus Zunovo Normalized: ocrevus zunovo |
Biological | Genentech USA, Inc. | $52.74 | 2 | 2025 |
Source payment records
|
|||||
| VYEPTI Normalized: vyepti |
Biological | Lundbeck LLC | $48.47 | 2 | 2025 |
Source payment records
|
|||||
| VYALEV Normalized: vyalev |
Drug | ABBVIE INC. | $44.41 | 2 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $38.39 | 2 | 2025 |
Source payment records
|
|||||
| Motpoly XR Normalized: motpoly xr |
Drug | Aucta Pharmaceuticals, Inc. | $26.77 | 1 | 2025 |
Source payment records
|
|||||
| Dynasplint Normalized: dynasplint |
Device | Dynasplint Systems Inc. | $25.33 | 1 | 2025 |
Source payment records
|
|||||
| NUPLAZID Normalized: nuplazid |
Drug | ACADIA Pharmaceuticals Inc | $21.79 | 1 | 2025 |
Source payment records
|
|||||
| AMYVID Normalized: amyvid |
Drug | Lilly USA, LLC | $20.90 | 1 | 2025 |
Source payment records
|
|||||
| VALTOCO Normalized: valtoco |
Drug | Neurelis, Inc. | $19.35 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | ABILIFY MAINTENA open payments reported associated product |
CMS Open Payments — General Payments 2902 supporting records · 986 recipient NPIs · example record 1251759994 |
Abilify Maintena · 2024 Exact normalized brand match · 1 Part D row |
57 | suppressed by CMS |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Quetiapine Fumarate | Quetiapine Fumarate | 390 | 58 |
| Trazodone Hcl | Trazodone Hcl | 243 | 57 |
| Clonazepam | Clonazepam | 224 | 45 |
| Alprazolam | Alprazolam | 210 | 42 |
| Lamotrigine | Lamotrigine | 207 | 42 |
| Aripiprazole | Aripiprazole | 195 | 44 |
| Benztropine Mesylate | Benztropine Mesylate | 179 | 33 |
| Risperidone | Risperidone | 158 | 33 |
| Fluoxetine Hcl | Fluoxetine Hcl | 134 | 26 |
| Divalproex Sodium Er | Divalproex Sodium | 133 | 21 |
| Sertraline Hcl | Sertraline Hcl | 131 | 25 |
| Olanzapine | Olanzapine | 130 | 30 |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 129 | 12 |
| Duloxetine Hcl | Duloxetine Hcl | 115 | 23 |
| Bupropion Xl | Bupropion Hcl | 107 | 21 |
| Lorazepam | Lorazepam | 105 | 31 |
| Buspirone Hcl | Buspirone Hcl | 104 | 26 |
| Divalproex Sodium | Divalproex Sodium | 103 | 13 |
| Invega Sustenna | Paliperidone Palmitate | 95 | 19 |
| Prazosin Hcl | Prazosin Hcl | 86 | 22 |
| Haloperidol | Haloperidol | 81 | 16 |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 81 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 79 | 11 |
| Citalopram Hbr | Citalopram Hydrobromide | 77 | 14 |
| Suboxone | Buprenorphine Hcl/Naloxone Hcl | 76 | suppressed |
| Mirtazapine | Mirtazapine | 73 | 13 |
| Clozapine | Clozapine | 69 | 12 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 62 | 12 |
| Abilify Maintena | Aripiprazole | 57 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 54 | 22 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 54 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 53 | 15 |
| Guanfacine Hcl Er | Guanfacine Hcl | 53 | suppressed |
| Paliperidone Er | Paliperidone | 50 | 12 |
| Diazepam | Diazepam | 48 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 48 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 47 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 45 | 11 |
| Gabapentin | Gabapentin | 42 | 12 |
| Haloperidol Decanoate | Haloperidol Decanoate | 36 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 36 | suppressed |
| Rexulti | Brexpiprazole | 36 | suppressed |
| Topiramate | Topiramate | 31 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 27 | suppressed |
| Naltrexone Hcl | Naltrexone Hcl | 27 | suppressed |
| Risperdal Consta | Risperidone Microspheres | 26 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 23 | suppressed |
| Temazepam | Temazepam | 23 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 22 | suppressed |
| Perphenazine | Perphenazine | 22 | suppressed |
| Desmopressin Acetate | Desmopressin Acetate | 21 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 20 | suppressed |
| Lithium Carbonate Er | Lithium Carbonate | 20 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 20 | suppressed |
| Pregabalin | Pregabalin | 20 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 20 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 19 | suppressed |
| Fluphenazine Hcl | Fluphenazine Hcl | 19 | suppressed |
| Vyvanse | Lisdexamfetamine Dimesylate | 19 | suppressed |
| Buprenorphine Hcl | Buprenorphine Hcl | 18 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 18 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 17 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 15 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 14 | suppressed |
| Carbamazepine Er | Carbamazepine | 14 | suppressed |
| Savella | Milnacipran Hcl | 14 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 14 | suppressed |
| Carbamazepine | Carbamazepine | 12 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 12 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,002.97 · 46 records | ABBVIE INC. | AMYVID, BRIUMVI, Dynasplint, KESIMPTA, KISUNLA, Leqembi, Motpoly XR, NUPLAZID, NURTEC ODT, Nayzilam, Ocrevus Zunovo, QULIPTA, UBRELVY, VALTOCO, VYALEV, VYEPTI, ZAVZPRET | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with Lundbeck LLC?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error